INT141894

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 5.50
Pain Relevance 0.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CSF3) extracellular region (CSF3) enzyme binding (CSF3)
Anatomy Link Frequency
blood 3
granulocyte 3
platelet 1
stem cell 1
CSF3 (Homo sapiens)
Pain Link Frequency Relevance Heat
dexamethasone 70 95.70 Very High Very High Very High
backache 6 91.12 High High
Central nervous system 67 89.12 High High
depression 1 66.04 Quite High
headache 8 65.84 Quite High
Paresthesia 1 62.08 Quite High
cva 7 47.68 Quite Low
corticosteroid 3 32.88 Quite Low
methotrexate 1 32.24 Quite Low
cytokine 4 26.08 Quite Low
Disease Link Frequency Relevance Heat
Toxicity 35 99.84 Very High Very High Very High
Adenocarcinoma 8 99.28 Very High Very High Very High
Cerebral Palsy 3 98.68 Very High Very High Very High
Breast Cancer 2 97.88 Very High Very High Very High
Neutropenia 6 97.80 Very High Very High Very High
Hemangioma 2 97.52 Very High Very High Very High
Anaemia 5 97.16 Very High Very High Very High
Low Back Pain 6 91.12 High High
Spasticity 1 90.84 High High
Fever 4 90.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas].
Localization (case) of granulocyte-colony stimulating factor in granulocyte associated with adenocarcinoma
1) Confidence 0.62 Published 2007 Journal Nippon Shokakibyo Gakkai Zasshi Section Title Doc Link 17283419 Disease Relevance 0.62 Pain Relevance 0.09
[A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas].
Localization (case) of granulocyte-colony stimulating factor in granulocyte associated with adenocarcinoma
2) Confidence 0.62 Published 2007 Journal Nippon Shokakibyo Gakkai Zasshi Section Title Doc Link 17283419 Disease Relevance 0.62 Pain Relevance 0.09
Stem cell sources were bone marrow (BM) in 122 patients (60.4%), peripheral blood (PB) after mobilization with granulocyte colony-stimulating factor in 52 (25.7%), and cord blood stem cells in 28 (13.4%).
Localization (mobilization) of granulocyte colony-stimulating factor in blood
3) Confidence 0.43 Published 2010 Journal The Korean Journal of Hematology Section Body Doc Link PMC2983044 Disease Relevance 0.38 Pain Relevance 0.27
With 65 evaluable patients, the combination of bortezomib, lenalidomide, and dexamethasone resulted in a 100% response rate and a 38% CR/nCR rate.50 A caveat of course, is that lenalidomide based induction regimens often result in inadequate stem cell harvests with granulocyte colony stimulating factor (GCSF) mobilization and therefore require cyclophosphamide or the recently FDA-approved CXCR inhibitor, plerixafor, to ensure adequate stem cell harvests.


Localization (mobilization) of GCSF in stem cell associated with dexamethasone
4) Confidence 0.28 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2990320 Disease Relevance 0.06 Pain Relevance 0.09
The use of epoetin alfa and granulocyte colony-stimulating factor generally is not recommended or required for treating neutropenia and anemia, adverse effects from pegINF/RBV.
Localization (use) of granulocyte colony-stimulating factor in granulocyte associated with neutropenia and anaemia
5) Confidence 0.10 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731021 Disease Relevance 2.05 Pain Relevance 0.10
In practice patients experiencing hematological toxicity can be managed safely with blood and platelet support and granulocyte colony stimulating factor (GCSF) and dose interruptions should not be necessary provided patients are closely monitored.
Localization (managed) of GCSF in platelet associated with toxicity
6) Confidence 0.09 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936263 Disease Relevance 0.78 Pain Relevance 0
Data from these studies indicate that Hospira filgrastim is well tolerated and may provide a clinically effective alternative to Amgen filgrastim for a range of indications in which G-CSF is routinely used.



Localization (tolerated) of filgrastim
7) Confidence 0.08 Published 2010 Journal Ann Hematol Section Body Doc Link PMC2924967 Disease Relevance 0.16 Pain Relevance 0
Data on CD34+ cells demonstrate that Hospira filgrastim is equivalent to Amgen filgrastim for the mobilization of peripheral blood progenitor cells (PBPCs).
Localization (mobilization) of filgrastim in blood
8) Confidence 0.07 Published 2010 Journal Ann Hematol Section Body Doc Link PMC2924967 Disease Relevance 0.06 Pain Relevance 0
In practice patients experiencing hematological toxicity can be managed safely with blood and platelet support and granulocyte colony stimulating factor (GCSF) and dose interruptions should not be necessary provided patients are closely monitored.
Localization (managed) of GCSF in blood associated with toxicity
9) Confidence 0.03 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936263 Disease Relevance 0.78 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox